In Week of Mar 28, 2026, Fermenta Biotech Ltd (Pharma - API) is outperforming Nifty 500 with +8.3% relative strength. Fundamentals: Average.
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
Based on Q3 FY26 earnings • Updated Feb 22, 2026
What: ₹110 crore capex for commercial-scale plant-based Vitamin D3 production with Indian patent protection
Impact: +₹50 Cr revenue
“On 10 December 2025, the Board approved INR 110 crore capex at Dahej for plant-based Vitamin D3 (with Indian patent protection), green chemistry enzymes (CAL-B Lipase and Penicillin G Acylase), and Vitamin D3 derivatives”
What: 46% YoY volume growth in human nutrition segment with operational leverage
Impact: +₹100 Cr revenue
“While human nutrition volumes grew by 43% in FY25 over FY24, we have further seen the volumes grow by 46% in 9MFY26 over 9MFY25. Our sustained volume momentum, combined with improving margins, positions Fermenta well for continued value creation”
What: Green chemistry sales in 9MFY26 surpassed full-year FY25 sales (₹9 cr vs ₹7 cr)
Impact: +₹15 Cr revenue
“Green chemistry sales in 9M FY26 surpassed those in full-year FY25, with 9M FY26 sales at INR 9 crore compared with INR 7 crore in FY25”
Earnings deceleration risks from management commentary
Trigger: Margin compression continues
Impact: -500 bps margin impact
Management view: Not directly addressed in available commentary, but concerning trend
Monitor: Q4 FY26 OPM
Trigger: US business remains unprofitable
Impact: -100 bps margin impact
Management view: Our US trading business subsidiary's 9MFY26 revenue was INR 37.5 crore, up 4% from a year ago, with EBITDA at INR 1.1 crore loss against INR 1.6 crore profit in the same period a year ago
Monitor: US subsidiary EBITDA
Trigger: Additional regulatory changes
Impact: -50 bps margin impact
Management view: On 21 November 2025, the Government of India notified four new Labour Codes, which have resulted in a one-time, exceptional expense of INR 2.19 crore towards employee benefits
Monitor: Exceptional items
Key quotes from recent conference calls
“On 10 December 2025, the Board approved INR 110 crore capex at Dahej for plant-based Vitamin D3 (with Indian patent protection), green chemistry enzymes (CAL-B Lipase and Penicillin G Acylase), and Vitamin D3 derivatives, reinforcing Fermenta's leadership in sustainable biocatalysis and Vitamin D3 innovation. — Management Commentary”
“Our sustained volume momentum, combined with improving margins, positions Fermenta well for continued value creation — Prashant Nagre, Managing Director”
“The turnaround of FY25 was further confirmed in 9MFY26. While growth of revenue, excluding that from real estate unlocking, was 57% in FY25 over FY24, in 9MFY26 revenue was already 96.9% of that achieved in full FY25. — Prashant Nagre, Managing Director”
“We remain focused on scaling our core human nutrition business while exploring strategic opportunities — Prashant Nagre, Managing Director”
Forward-looking targets from management for FY27
Capex Plan
₹110 Cr
Key Milestones
• Dahej plant commissioning
• Human nutrition volume growth
• Green chemistry scaling
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | -12% | +6% | Inflection Down |
| PAT (Net Profit) | -68% | +72% | Inflection Down |
| OPM | 18.0% | -1600 bps | Volatile |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Feb 22, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
Fermenta Biotech Ltd's latest quarterly results (Dec 2025) show
Fermenta Biotech Ltd's profit is declining with an inflecting downward trend.
Fermenta Biotech Ltd's revenue growth trend is inflecting downward.
Fermenta Biotech Ltd's operating margin is volatile.
Fermenta Biotech Ltd's long-term compounding rates
Fermenta Biotech Ltd's earnings growth is inflecting downward with negative momentum on a sequential basis.
Fermenta Biotech Ltd's trailing twelve month (TTM) performance
Fermenta Biotech Ltd appears significantly undervalued based on our fair value analysis.
Fermenta Biotech Ltd's current PE ratio is 11.4x.
Fermenta Biotech Ltd's current PE is 11.4x.
Fermenta Biotech Ltd's price-to-book ratio is 2.6x.
Fermenta Biotech Ltd is rated Average with a fundamental score of 40.72/100. This score is calculated from objective financial metrics
Fermenta Biotech Ltd has a debt-to-equity ratio of N/A.
Fermenta Biotech Ltd's return ratios over recent years
Fermenta Biotech Ltd's operating cash flow is positive (FY2025).
Fermenta Biotech Ltd's current dividend yield is 0.73%.
Fermenta Biotech Ltd's shareholding pattern (Dec 2025)
Fermenta Biotech Ltd's promoter holding has remained stable recently.
Fermenta Biotech Ltd has been outperforming Nifty 500 for 2 consecutive weeks, indicating early-stage outperformance.
Fermenta Biotech Ltd is a re-entry — it briefly dropped off the outperformance list but has now returned. Re-entries can signal renewed strength.
Fermenta Biotech Ltd has 3 key growth catalysts identified from recent earnings analysis
Fermenta Biotech Ltd has 3 key risks worth monitoring
In Q3 FY26, Fermenta Biotech Ltd's management highlighted
Fermenta Biotech Ltd's management has provided the following forward guidance for FY27
Based on quantitative research signals, here is why Fermenta Biotech Ltd may be worth studying
Fermenta Biotech Ltd investment thesis summary:
Fermenta Biotech Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
